Showing 1 - 20 results of 34 for search 'Binghe Xu', query time: 0.41s
Refine Results
-
1
-
2
Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer by Yiqun Han, Jiayu Wang, Binghe Xu
Published 2023-02-01
Article -
3
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy by Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu
Published 2023-01-01
Article -
4
The road toward breast cancer single‐disease quality control in China by Bo Lan, Qiao Li, Fei Ma, Binghe Xu
Published 2023-10-01
Article -
5
-
6
Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer by Tong Wei, Yikun Kang, Xue Wang, Jian Yue, Binghe Xu, Peng Yuan
Published 2024-03-01
Article -
7
-
8
Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study by Di Zhang, Jingtong Zhai, Lixi Li, Yun Wu, Fei Ma, Binghe Xu
Published 2022-11-01
Article -
9
-
10
Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Canc... by Yue Chai, Yujie Chen, Di Zhang, Yuce Wei, Zhijun Li, Qiao Li, Binghe Xu
Published 2022-02-01
Article -
11
Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites: A population‐based study in patients with breast can... by Yue Chai, Yujie Chen, Jiaxuan Liu, Maiyue He, Mingxia Jiang, Binghe Xu, Qiao Li
Published 2023-09-01
Article -
12
-
13
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib fo... by Yiqun Han, Jiayu Wang, Tao Sun, Quchang Ouyang, Jianwen Li, Jie Yuan, Binghe Xu
Published 2023-11-01
Article -
14
-
15
New insights into HER2-low breast cancer brain metastasis: A retrospective analysis by Hangcheng Xu, Yan Wang, Li Li, Yiqun Han, Yun Wu, Qiang Sa, Binghe Xu, Jiayu Wang
Published 2024-02-01
Article -
16
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis by Danyang Ji, Yang Luo, Jiayu Wang, Shanshan Chen, Bo Lan, Fei Ma, Binghe Xu, Ying Fan
Published 2023-08-01
Article -
17
-
18
-
19
Combined chemo-endocrine therapy as a potential new option for HR+/HER2− advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine by Xue Wang, Jian Yue, Yikun Kang, Zhong Dai, Jie Ju, Jiayu Wang, Pin Zhang, Fei Ma, Binghe Xu, Peng Yuan
Published 2023-04-01
Article -
20
A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer by Yue Chai, Jiaxuan Liu, Mingxia Jiang, Maiyue He, Zijing Wang, Fei Ma, Jiayu Wang, Peng Yuan, Yang Luo, Binghe Xu, Qiao Li
Published 2023-08-01
Article